You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

31 Results
Guidelines and Advice
Status: In-Review
ID: GL 2-26
Version: 3
Aug 2022
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022
Guidelines and Advice
Jan 2022
Drug
Other Name(s): BiCNU®
Oct 2022
Drug
Other Name(s): Xalkori®
Jan 2022
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin with Carboplatin - Platinum-Sensitive Recurrent Ovarian Fallopian Tube and Primary Peritoneal Cancer
Jun 2022
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Apr 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    dexamethasone
May 2022

Pages